JBCHEPHARM • Health Care
ROCE
21.92%
FY24 Actual
D/E Ratio
0.00
Zero Debt
5Y Rev CAGR
14.3%
High Growth
Profit Margin
| Metrics (Values in Cr) | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 2,463.47 | 3,159.22(+28.2%) |
15.6%
5Y Average
3,956.31(+12.3%) |
4,207.94(+6.4%) |
4,207.94 |
| Operating Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Profit | — | — | — | — | — | — |
| Raw Profit | 860.38 | 1,179.2(+37.1%) | 1,228.9(+4.2%) | 1,316.97(+7.2%) | 1,390.34(+5.6%) | — |
| Operating Expenses | 150.79 | 190.53(+26.4%) | 166.96(-12.4%) | 238.69(+43.0%) | 217.58(-8.8%) | 3,067.55 |
| Selling General And Administrative Expenses | 358.9 | 448.81(+25.1%) | 501.94(+11.8%) | 558.92(+11.4%) | 602.91(+7.9%) | — |
| Depreciation And Amortization | 72.66 | 114.41(+57.5%) | 138.32(+20.9%) | 171.04(+23.7%) | 182.5(+6.7%) | 182.5 |
| Profit Before Interest | 510.03 | 591.28(+15.9%) | 795.84(+34.6%) | 899.13(+13.0%) | 957.9(+6.5%) | 957.89 |
| Interest Expense | 5.12 | 36.05(+604.1%) | 44.33(+23.0%) | 11.73(-73.5%) | 5.57(-52.5%) | 5.57 |
| Profit Before Tax | 504.91 | 555.23(+10.0%) | 751.51(+35.4%) | 887.4(+18.1%) | 952.33(+7.3%) | 952.32 |
| Tax Expense | 119.54 | 145.4(+21.6%) | 198.88(+36.8%) | 227.8(+14.5%) | 242.86(+6.6%) | 242.86 |
| Net Income | 385.37 | 409.83(+6.3%) | 552.63(+34.8%) | 659.6(+19.4%) | 709.47(+7.6%) | 709.46 |
| Earnings Per Share | 24.933 | 26.499(+6.3%) | 35.659(+34.6%) | 42.435(+19.0%) | 44.87(+5.7%) | 44.187 |
| Dividends Per Share | 8.25 | 8.875(+7.6%) | 12.25(+38.0%) | 15.5(+26.5%) | 22(+41.9%) | 19.7 |
| Payout Ratio | 0.331 | 0.335(+1.2%) | 0.344(+2.6%) | 0.365(+6.3%) | 0.49(+34.2%) | 0.446 |